Musaffa Logo
LuxExperience BV LUXE
$7.77 $0.09 (1.15%) 1D

Last Updated: Aug 21, 12:00 AM·NYSE

Pricing for US stocks is delayed by 24 hours

LUXE Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, LuxExperience BV is classified as not halal.

NOT HALAL

Report Source: undefined Quarter Report

LuxExperience BV

LuxExperience BV. Stock Analysis LUXE

United States Consumer Discretionary Small Cap

LuxExperience BV (LUXE) Chart

Financial Metrics & Statements of LuxExperience BV (LUXE)

FAQ's for LuxExperience BV (LUXE)

  • As of August 2026, LuxExperience BV LUXE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes LuxExperience BV using these criteria to determine its compliance status.
  • Muslim investors may consider investing in LuxExperience BV if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of LuxExperience BV by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of LuxExperience BV may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of LuxExperience BV on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.